These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 26487965)

  • 1. Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors.
    Kleponis J; Skelton R; Zheng L
    Cancer Biol Med; 2015 Sep; 12(3):201-8. PubMed ID: 26487965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Herzberg B; Campo MJ; Gainor JF
    Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.
    Kyi C; Postow MA
    Immunotherapy; 2016 Jun; 8(7):821-37. PubMed ID: 27349981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment.
    Tunger A; Kießler M; Wehner R; Temme A; Meier F; Bachmann M; Schmitz M
    Biomedicines; 2018 Mar; 6(1):. PubMed ID: 29494517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.
    Chen X; Pan X; Zhang W; Guo H; Cheng S; He Q; Yang B; Ding L
    Acta Pharm Sin B; 2020 May; 10(5):723-733. PubMed ID: 32528824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic therapy for esophagogastric cancer: immune checkpoint inhibition.
    Lyons TG; Ku GY
    Chin Clin Oncol; 2017 Oct; 6(5):53. PubMed ID: 29129093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Blockade in Breast Cancer Therapy.
    Bu X; Yao Y; Li X
    Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer.
    Niyongere S; Saltos A; Gray JE
    J Thorac Dis; 2018 Feb; 10(Suppl 3):S433-S450. PubMed ID: 29593889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors.
    Chen JA; Ma W; Yuan J; Li T
    Cancer Treat Res; 2020; 180():251-279. PubMed ID: 32215873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of immune checkpoint inhibitors].
    Kitano S
    Rinsho Ketsueki; 2017; 58(8):966-976. PubMed ID: 28883282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cell checkpoint regulators in the heart.
    Grabie N; Lichtman AH; Padera R
    Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors for immunotherapy in melanoma.
    Teixidó C; González-Cao M; Karachaliou N; Rosell R
    Ann Transl Med; 2015 Sep; 3(15):208. PubMed ID: 26488004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.
    Srinivasan P; Wu X; Basu M; Rossi C; Sandler AD
    PLoS Med; 2018 Jan; 15(1):e1002497. PubMed ID: 29377881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors.
    Weber R; Fleming V; Hu X; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
    Front Immunol; 2018; 9():1310. PubMed ID: 29942309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers.
    Suzuki S; Ogawa T; Sano R; Takahara T; Inukai D; Akira S; Tsuchida H; Yoshikawa K; Ueda R; Tsuzuki T
    Cancer Sci; 2020 Jun; 111(6):1943-1957. PubMed ID: 32304268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.